Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies
Lists
Only you see this
Abstract
The used doses of C/T in this study were higher than those approved by the U.S. FDA, while clinical success is uncertain. Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration.
BibTeX
@inproceedings{nekidy2023clinical,
author = {Wasim S. El Nekidy and Mooza Al Ali and Emna Abidi and Islam M. Ghazi and Nizar Attallah and Rania El Lababidi and Fadi Hijazi and Jihad Mallat},
title = {{Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies}},
booktitle = {Clinical},
year = {2023},
doi = {10.5414/cn111166},
}Loading related content...